ALX Oncology (ALXO) News Today $1.27 +0.06 (+4.96%) Closing price 04:00 PM EasternExtended Trading$1.20 -0.08 (-5.91%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALXO Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period CEO & Director of ALX Oncology Holdings Picks Up 69% More StockSeptember 21 at 9:36 PM | finance.yahoo.comALX Oncology (NASDAQ:ALXO) CEO Jason Lettmann Purchases 21,070 SharesSeptember 19 at 5:47 PM | marketbeat.comALX Oncology (NASDAQ:ALXO) CEO Jason Lettmann Acquires 71,163 SharesSeptember 19 at 5:46 PM | marketbeat.comALX Oncology (NASDAQ:ALXO) CEO Acquires $22,544.90 in StockSeptember 19 at 7:52 AM | insidertrades.comALX Oncology appoints Klencke as interim CMOSeptember 12, 2025 | msn.comALX Oncology Appoints Dr. Barbara Klencke as Interim Chief Medical Officer Following Departure of Dr. Alan SandlerSeptember 12, 2025 | quiverquant.comQALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical OfficerSeptember 12, 2025 | globenewswire.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Down 63.6% in AugustSeptember 6, 2025 | marketbeat.comMPM Bioimpact LLC Lowers Stake in ALX Oncology Holdings Inc. $ALXOSeptember 4, 2025 | marketbeat.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of "Moderate Buy" from AnalystsSeptember 1, 2025 | marketbeat.comALX Oncology to Participate in Upcoming Investor Conferences in SeptemberAugust 29, 2025 | globenewswire.comALX Oncology doses first patient in Phase 1 trial for ALX2004August 19, 2025 | msn.comALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid TumorsAugust 19, 2025 | globenewswire.comALX Oncology Advances Cancer Therapy PipelineAugust 13, 2025 | msn.comALX Oncology Appoints Dr. Curran to BoardAugust 12, 2025 | msn.comALX Oncology Holdings Inc. (ALXO) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 12, 2025 | globenewswire.com6ALXO : ALX Oncology Holdings's Earnings: A PreviewAugust 11, 2025 | benzinga.comALX Oncology Holdings Inc. to Report Second Quarter 2025 Financial Results and Business Update on August 12, 2025August 5, 2025 | quiverquant.comQALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025August 5, 2025 | globenewswire.comALX Oncology Holdings Inc. (ALXO) - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comALX Oncology to Present at the Jefferies 2025 Global Healthcare ConferenceMay 30, 2025 | globenewswire.comALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast EventMay 20, 2025 | globenewswire.comALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025May 13, 2025 | globenewswire.comALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 8, 2025 | finance.yahoo.comALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 8, 2025 | globenewswire.com3ALXO : What's Next: ALX Oncology Holdings's Earnings PreviewMay 7, 2025 | benzinga.comALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025May 2, 2025 | globenewswire.comALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trialsApril 28, 2025 | finance.yahoo.comALX Oncology's Phase 2 Trials In Head & Neck Cancer Fail To Meet Primary EndpointsApril 27, 2025 | nasdaq.comEvorpacept fails to meet trial endpoints in HNSCCApril 26, 2025 | investing.comALX Oncology reports ASPEN-03, ASPEN-04 trials did not meet primary endpointsApril 26, 2025 | markets.businessinsider.comALX Oncology reports ‘encouraging’ final results from Phase 1 evorpacept trialApril 26, 2025 | markets.businessinsider.comALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin LymphomaApril 25, 2025 | globenewswire.comALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary EndpointsApril 25, 2025 | globenewswire.comALX Oncology receives IND clearance from FDA for ALX2004April 8, 2025 | markets.businessinsider.comALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug ConjugateApril 7, 2025 | markets.businessinsider.comALX Oncology (NASDAQ:ALXO) Price Target Cut to $1.50 by Analysts at Stifel NicolausMarch 8, 2025 | marketbeat.comALX Oncology files $364.12M mixed securities shelfMarch 8, 2025 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for ALX Oncology (NASDAQ:ALXO)March 8, 2025 | marketbeat.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of "Moderate Buy" by BrokeragesMarch 8, 2025 | marketbeat.comALX Oncology Holdings Insider Trading Activity | NASDAQ:ALXO | BenzingaMarch 7, 2025 | benzinga.comALX Oncology (NASDAQ:ALXO) Announces Quarterly Earnings Results, Beats Estimates By $0.17 EPSMarch 7, 2025 | marketbeat.comALX Oncology (NASDAQ:ALXO) Given New $9.00 Price Target at Piper SandlerMarch 7, 2025 | marketbeat.comALX Oncology (NASDAQ:ALXO) Upgraded to "Buy" at Jefferies Financial GroupMarch 7, 2025 | marketbeat.comALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 6, 2025 | globenewswire.comBay Area biotech firm once worth more than $4B lays off 30% of staffMarch 6, 2025 | msn.comALX Oncology price target raised to $9 from $8 at Piper SandlerMarch 6, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and Elicio Therapeutics (ELTX)March 6, 2025 | markets.businessinsider.comALX Oncology upgraded to Buy from Hold at JefferiesMarch 6, 2025 | markets.businessinsider.com Get ALX Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALXO Media Mentions By Week ALXO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALXO News Sentiment▼1.440.73▲Average Medical News Sentiment ALXO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALXO Articles This Week▼62▲ALXO Articles Average Week Get the Latest News and Ratings for ALXO and Related Stocks Enter your email address to receive the latest news and analysts' ratings for ALX Oncology and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Puma Biotechnology News Today Aerovate Therapeutics News Today Organigram Global News Today Vor Biopharma News Today Sagimet Biosciences News Today CARGO Therapeutics News Today GENFIT News Today Aclaris Therapeutics News Today SOPHiA GENETICS News Today Entrada Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALXO) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ALX Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
